Why the study?
Does AAV-CTLA4Ig gene transduction prolong allograft survival in mouse cardiac grafts?
Does AAV-CTLA4Ig gene transduction prolong allograft survival in mouse cardiac grafts?
Answers are grounded in this paper and cite their sources.
AAV-mediated CTLA4Ig gene transfer to donor hearts significantly prolongs allograft survival in a mouse model, suggesting a potential approach to prevent rejection.
Organ grafts transduced with gene-encoding immunosuppressive molecules are a less toxic approach to preventing graft rejection. Adenovirus vectors have been widely tested with unsatisfactory results, while adeno-associated virus (AAV) is smaller and elicits a low host humoral response. We constructed an AAV vector containing the mouse CTLA4Ig gene. B10 (H2(b)) cardiac grafts were transduced with AAV-CTLA4Ig by coronary infusion. AAV-LacZ vectors were used as reporters and controls, and the expression of beta-gal was determined by X-gal staining. Thirty percent to 40% of myocytes displayed strongly positive X-gal staining after infusion with AAV-LacZ. Additional infusion with vascular dilator reagents did not improve the transduction rate. Survival of B10 heart allografts transduced with AAV-CTLA4-Ig was significantly prolonged in C3H (H2(k)) recipients. These data demonstrate that AAV vectors can efficiently be transduced into the mouse myocardium by coronary infusion. Graft transduction with AAV-CTLA4Ig may be a novel approach to preventing allograft rejection.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: